Melbourne, Victoria – Alcidion Group Limited (ASX: ALC) today advises it has released the attached investor presentation and business update, which will be presented to investors this week by Managing Director Kate Quirke.
Highlights from the presentation include:
- Two contracts signed in Q3 since the release of the Appendix 4C, adding a further $1 million of sold revenue to be recognised in FY2020
- An increasing market opportunity showing continued investment in digital health across Alcidion’s current markets and details of Alcidion’s expansion strategy
- Update on Q3 activities, including the planned launch of Miya MEMRe in the UK
Alcidion Managing Director Kate Quirke will be meeting with investors in Sydney and Melbourne from Tuesday 11th February to Thursday 13th February 2020.
For further information, please contact:
Ph: +61 401 018 828
Ph: +61 439 162369
Alcidion Limited (ASX:ALC) has a simple purpose: to transform healthcare with smart, intuitive technology solutions that meet the needs of hospital and allied healthcare, worldwide. It offers a complementary set of software products and services that create a unique offering in the global healthcare market; solutions that support interoperability, allow communication and task management, and deliver clinical decision support at the point of care to improve patient outcomes. In 2017 Alcidion acquired Oncall System and its Smartpage clinical communication system. In 2018 it acquired the Patientrack bedside patient monitoring software and MKM Health, an IT solutions and services provider. These offerings now operate under the Alcidion brand. With over 25 years of combined healthcare experience, Alcidion brings together the very best in technology and market knowledge to deliver solutions that make healthcare better for everyone.
© Alcidion Group Limited 2020. Alcidion, MKM Health, Miya, Patientrack and Smartpage are registered trademarks. All other brands and product names and trademarks are the registered property of their respective companies.
This announcement is authorised for release by the Board of Directors of Alcidion Limited.